作者更正:β-catenin 赋予结肠癌对 PI3K/AKT 抑制剂的耐药性
Author Correction: β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer
Nature Medicine 发表更正通知,修正了第 6b 图中 T49 Xenograft 图像与图 1b 重复的错误。修正后的图像已替换为对应染色描述的代表性共聚焦图片,该通知旨在更正原文的图像错误。
Correction to: Nature Medicine https://doi.org/10.1038/nm.2772, published online 20 May 2012.
In the version of the article initially published, the “T49, Xenograft” image in Fig. 6b was a duplicate of the image in Fig. 1b. A corrected version of Fig. 6b is shown below as Fig. 1, where the “T49, Xenograft” image has been replaced with a different representative confocal image corresponding to the staining described in that panel. This notice serves to amend the error.
Corrected Fig. 6b.
Author information
Author notes
Paloma Ordóñez-Morán
Present address: Swiss Institute for Experimental Cancer Research, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
These authors contributed equally: Stephan P. Tenbaum, Paloma Ordóñez-Morán, Isabel Puig.
Authors and Affiliations
Vall d’Hebrón Institut d’Oncología (VHIO), Stem Cell and Cancer Laboratory, Barcelona, Spain
Stephan P. Tenbaum, Isabel Puig, Irene Chicote, Oriol Arqués & Héctor G. Palmer
Instituto de Investigaciones Biomédicas ‘Alberto Sols’, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain
Paloma Ordóñez-Morán & Alberto Muñoz
Department of Pathology, Hospital Universitari Vall d’Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain
Stefania Landolfi & Santiago Ramón y. Cajal
Group of Drug Delivery and Targeting, Centro de Investigaciones en Bioquímica y Biología Molecular (CIBBIM)–Nanomedicine and Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Hospital Universitari Vall d’Hebrón, Institut de Recerca Vall d’Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain
Yolanda Fernández & Simó Schwartz Jr
Parc de Recerca Biomèdica de Barcelona (PRBB), Centre d´Imatge Molecular (CRC) Corporació Sanitària, Barcelona, Spain
José Raúl Herance, Juan D. Gispert & Santiago Rojas
VHIO, Genomics Cancer Group, Barcelona, Spain
Leire Mendizabal & Ana Vivancos
Centre for Respiratory Research, Rayne Institute, University College London, London, UK
Susana Aguilar
Hematopoietic Stem Cell Laboratory, London Research Institute, Cancer Research UK, London, UK
Susana Aguilar
General Surgery Service, Hospital Universitari Vall d’Hebrón, Barcelona, Spain
Eloy Espín
Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts, USA
José Baselga
Howard Hughes Medical Institute, Chevy Chase, Maryland, USA
José Baselga
Medical Oncology Department, Hospital Universitari Vall d’Hebrón, Barcelona, Spain
Josep Tabernero
Authors
- Stephan P. Tenbaum
- Paloma Ordóñez-Morán
- Isabel Puig
- Irene Chicote
- Oriol Arqués
- Stefania Landolfi
- Yolanda Fernández
- José Raúl Herance
- Juan D. Gispert
- Leire Mendizabal
- Susana Aguilar
- Santiago Ramón y. Cajal
- Simó Schwartz Jr
- Ana Vivancos
- Eloy Espín
- Santiago Rojas
- José Baselga
- Josep Tabernero
- Alberto Muñoz
- Héctor G. Palmer
Corresponding author
Correspondence to Héctor G. Palmer.
About this article
Cite this article
Tenbaum, S.P., Ordóñez-Morán, P., Puig, I. et al. Author Correction: β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med (2026). https://doi.org/10.1038/s41591-026-04750-7
Published: 22 October 2026
Version of record: 22 October 2026
DOI: https://doi.org/10.1038/s41591-026-04750-7
来源:Nature Medicine · nature.com